| Name | Title | Contact Details |
|---|
NEXT MOVE GEAR LLC is a Evanston, IL-based company in the Business Services sector.
Today, Greiner Packaging numbers among the most important European packaging processors. Locations in many European countries grant our customers the shortest production and lead times. The head office of Greiner Packaging International is situated in Sattledt, Austria. IMPRINT Greiner Packaging International GmbH Greinerstraße 70, A-4550 Kremsmünster Contact: Phone: +43 50541 84212 Fax: +43 7583 60 08 E-Mail: office@greiner-gpi.com Website: www.greiner-gpi.com Commercial register court: Landesgericht Steyr Commercial register number: 176889g Data processing register number: 1005936 VAT ID number: ATU 45836305 CEO: Beatrix Praeceptor Infohotline: +43 50541 84212 Authority acc. to the Austrian E-commerce law (ECG): BH Kirchdorf a.d. Krems Chamber: Economic Chamber of Upper Austria Business object: •Development, production, and trading with packagings, plastics and machinery of all kinds, in particular under the registered "Greiner" brand; •Acquisition, holding and administration of other associated companies and enterprises, in particular in the form of a holding; •Rendering management services and other concern-related services.
New Age Images Inc is a Miami, FL-based company in the Business Services sector.
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN